Freeline Therapeutics (FRLN)

AI Score

Unlock

6.49

0.01 (0.15%)

At close: Feb 16, 2024, 8:37 PM

Freeline Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.

Fiscal Year	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q2 2021	Q1 2021	Q4 2020	Q3 2020	Q2 2020	Q1 2020	Q2 2019	Q1 2019	Q2 2018	Q1 2018
Period Ending	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Jun 30, 2019	Mar 31, 2019	Jun 30, 2018	Mar 31, 2018
Revenue	5K	617K	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Cost of Revenue	383.76K	434.39K	322.9K	317.36K	402.54K	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Gross Profit	-378.76K	182.61K	-322.9K	-317.36K	-402.54K	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Operating Income	-12.27M	-15.65M	-20.08M	-19.88M	-23.51M	-26.89M	-28.17M	-34.33M	-35.3M	-38.81M	-33.94M	-32.26M	-29.08M	-19.92M	-21.19M	-15.91M	-15.91M	-10.25M	-10.25M
Interest Income	98K	34K	206K	273K	296K	251K	84K	n/a	85K	125K	140K	131K	n/a	n/a	53K	n/a	n/a	n/a	n/a
Pretax Income	-12.05M	-16M	1.33M	-22.73M	-14.84M	-24.32M	-26.71M	-34.39M	-30.86M	-39.86M	-34.94M	-38.02M	-24.91M	-16.69M	-16.57M	-13.44M	-13.44M	-8.31M	-8.31M
Net Income	-12.09M	-16.01M	1.17M	-23M	-14.89M	-24.35M	-26.73M	-34.7M	-30.88M	-39.87M	-34.95M	-38.08M	-24.98M	-16.56M	-16.7M	-13.48M	-13.48M	-8.32M	-8.32M
Selling & General & Admin	6.4M	9.5M	8.05M	5.64M	8.73M	8.05M	8.22M	7.35M	12.6M	14.54M	10.08M	11.38M	3.26M	7.93M	3.73M	4.15M	4.15M	1.7M	1.7M
Research & Development	5.79M	8.83M	10.89M	12.64M	14.78M	18.84M	19.95M	24.6M	22.7M	24.27M	23.86M	20.88M	25.82M	11.99M	17.46M	11.76M	11.76M	8.55M	8.55M
Other Expenses	-34K	-591K	-261K	-267K	-583K	-335K	-386K	-658K	3.86M	-1.63M	-1.73M	-10.04M	-114K	-1K	863K	-31.82M	-31.82M	-20.49M	-20.49M
Operating Expenses	12.03M	18.12M	18.68M	18.02M	22.93M	26.56M	27.79M	31.4M	34.81M	38.35M	33.34M	28.12M	24.85M	16.73M	17.49M	-15.91M	-15.91M	-10.25M	-10.25M
Interest Expense	n/a	n/a	n/a	6.39M	296K	251K	n/a	n/a	85K	n/a	n/a	n/a	56K	n/a	n/a	n/a	n/a	n/a	n/a
Selling & Marketing Expenses	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Cost & Expenses	12.03M	18.12M	18.68M	18.02M	22.93M	26.56M	27.79M	31.4M	34.81M	38.35M	33.34M	28.12M	24.85M	16.73M	17.49M	15.91M	15.91M	10.25M	10.25M
Income Tax Expense	41K	6K	162K	272K	50K	24K	22K	313K	13K	7K	9K	55K	74K	-131K	131K	35.25K	35.25K	6.75K	6.75K
Shares Outstanding (Basic)	4.36M	4.34M	4.34M	4.33M	4.33M	4.3M	2.84M	2.38M	2.38M	2.38M	2.38M	2.39M	2.32M	2.29M	423.19K	21.35M	21.35M	21.35M	21.35M
Shares Outstanding (Diluted)	4.36M	4.34M	4.34M	4.33M	4.33M	4.3M	2.84M	2.38M	2.38M	2.38M	2.38M	2.39M	2.32M	2.29M	423.19K	21.35M	21.35M	21.35M	21.35M
EPS (Basic)	-2.77	-3.69	0.30	-5.31	-3.44	-5.66	-9.4	-14.56	-12.96	-16.76	-14.7	-15.93	-10.78	-7.24	-39.47	-0.63	-0.63	-0.39	-0.39
EPS (Diluted)	-2.77	-3.69	0.30	-5.31	-3.44	-5.66	-9.4	-14.56	-12.96	-16.76	-14.7	-15.93	-10.78	-7.24	-39.47	-0.63	-0.63	-0.39	-0.39
EBITDA	-11.56M	-19.13M	-37.51M	-16.03M	-22.52M	-26.08M	-27.24M	-30.79M	-34.22M	-37.74M	-32.77M	-27.53M	-24.38M	-16.36M	-16.99M	-13.06M	-13.06M	-8.07M	-8.07M
EBIT	n/a	n/a	-37.83M	-14.89M	-14.55M	-23.84M	-27.79M	-34.47M	-31.35M	n/a	n/a	-38.14M	-29.14M	n/a	n/a	n/a	n/a	n/a	n/a
Depreciation & Amortization	386K	433K	-17.42M	3.85M	988K	814K	927K	611K	588K	618K	573K	585K	466K	367K	495K	385K	385K	242.5K	242.5K